BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Locatelli F, Del Vecchio L. Erythropoiesis-stimulating agents in renal medicine. Oncologist 2011;16 Suppl 3:19-24. [PMID: 21930831 DOI: 10.1634/theoncologist.2011-S3-19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Zou H, Banerjee P, Leung SSY, Yan X. Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. Front Pharmacol 2020;11:997. [PMID: 32719604 DOI: 10.3389/fphar.2020.00997] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Al-ali FS, El-sayed Abdelfattah M, Fawzy AA, Hamdy AF, Abdulla AE. Erythropoietin-stimulating agents in the management of anemia of end-stage renal disease patients on regular hemodialysis: A prospective randomized comparative study from Qatar: Erythropoietin-stimulating agents’ comparison. Hemodial Int 2015;19:33-43. [DOI: 10.1111/hdi.12181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
4 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Yang Y, Yu B, Chen Y. Blood disorders typically associated with renal transplantation. Front Cell Dev Biol. 2015;3:18. [PMID: 25853131 DOI: 10.3389/fcell.2015.00018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
6 Yan X, Ait-Oudhia S, Krzyzanski W. Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness. Pharm Res 2013;30:1026-36. [PMID: 23187865 DOI: 10.1007/s11095-012-0938-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics 2014;8:155-67. [PMID: 24790409 DOI: 10.2147/BTT.S27578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Hahn D, Esezobor CI, Elserafy N, Webster AC, Hodson EM. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev 2017;1:CD011690. [PMID: 28066881 DOI: 10.1002/14651858.CD011690.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Lappin T. The changing face of anemia treatment. Oncologist 2011;16 Suppl 3:1-2. [PMID: 21930828 DOI: 10.1634/theoncologist.2011-S3-1] [Reference Citation Analysis]
10 Al-Khalaf B, Al-Khalaf N, Mustafa S. Effect of ethnicity on erythropoietin therapy response for hemodialysis patients: a retrospective study. Hemodial Int 2013;17:510-6. [PMID: 23095132 DOI: 10.1111/j.1542-4758.2012.00763.x] [Reference Citation Analysis]